Detailed information for compound 54776

Basic information

Technical information
  • TDR Targets ID: 54776
  • Name: 1-[(2S)-1-oxo-3-phenyl-1-(4-pyridin-2-ylpiper azin-1-yl)propan-2-yl]-3-(2-sulfanylidene-3H- 1,3,4-thiadiazol-5-yl)urea
  • MW: 469.583 | Formula: C21H23N7O2S2
  • H donors: 2 H acceptors: 5 LogP: 2.56 Rotable bonds: 9
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C(N[C@H](C(=O)N1CCN(CC1)c1ccccn1)Cc1ccccc1)Nc1nnc(s1)S
  • InChi: 1S/C21H23N7O2S2/c29-18(28-12-10-27(11-13-28)17-8-4-5-9-22-17)16(14-15-6-2-1-3-7-15)23-19(30)24-20-25-26-21(31)32-20/h1-9,16H,10-14H2,(H,26,31)(H2,23,24,25,30)/t16-/m0/s1
  • InChiKey: BTSWLXDOHMNQBM-INIZCTEOSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 1-[(1S)-1-benzyl-2-oxo-2-[4-(2-pyridyl)piperazin-1-yl]ethyl]-3-(2-thioxo-3H-1,3,4-thiadiazol-5-yl)urea
  • 1-[(1S)-1-benzyl-2-oxo-2-[4-(2-pyridyl)-1-piperazinyl]ethyl]-3-(2-thioxo-3H-1,3,4-thiadiazol-5-yl)urea
  • 1-[(1S)-1-benzyl-2-keto-2-[4-(2-pyridyl)piperazino]ethyl]-3-(2-thioxo-3H-1,3,4-thiadiazol-5-yl)urea
  • 1-[(2S)-1-oxo-3-phenyl-1-(4-pyridin-2-ylpiperazin-1-yl)propan-2-yl]-3-(5-sulfanylidene-4H-1,3,4-thiadiazol-2-yl)urea
  • 1-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridyl)piperazin-1-yl]ethyl]-3-(5-thioxo-4H-1,3,4-thiadiazol-2-yl)urea
  • 1-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridyl)-1-piperazinyl]ethyl]-3-(5-thioxo-4H-1,3,4-thiadiazol-2-yl)urea
  • 1-[(1S)-1-(benzyl)-2-keto-2-[4-(2-pyridyl)piperazin-1-yl]ethyl]-3-(5-thioxo-4H-1,3,4-thiadiazol-2-yl)urea

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens matrix metallopeptidase 3 (stromelysin 1, progelatinase) Starlite/ChEMBL References
Homo sapiens matrix metallopeptidase 1 (interstitial collagenase) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus matrix metallopeptidase 7 M10 family matrix metallopeptidase 3 (stromelysin 1, progelatinase) 477 aa 431 aa 34.6 %
Brugia malayi Matrixin family protein matrix metallopeptidase 1 (interstitial collagenase) 403 aa 401 aa 27.7 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Leishmania major telomerase reverse transcriptase, putative 0.29 0.2651 0.5
Giardia lamblia Telomerase catalytic subunit 0.29 0.2651 0.5
Echinococcus multilocularis protection of telomeres protein 1 0.0587 0.0448 1
Plasmodium vivax telomerase reverse transcriptase, putative 0.29 0.2651 0.5
Toxoplasma gondii RNA-directed DNA polymerase 0.29 0.2651 0.5
Trypanosoma brucei telomerase reverse transcriptase 0.29 0.2651 0.5
Loa Loa (eye worm) matrixin family protein 0.0127 0.001 1
Brugia malayi Telomerase reverse transcriptase 0.7718 0.7238 1
Plasmodium falciparum telomerase reverse transcriptase 0.29 0.2651 0.5
Trypanosoma cruzi telomerase reverse transcriptase, putative 0.29 0.2651 0.5
Echinococcus granulosus protection of telomeres protein 1 0.0587 0.0448 1
Trypanosoma cruzi telomerase reverse transcriptase, putative 0.29 0.2651 0.5

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 0.52 uM Binding affinity for matrix metalloproteinase-3 ChEMBL. 10229623
Ki (binding) = 0.52 uM Binding affinity for matrix metalloproteinase-3 ChEMBL. 10229623
Ki (binding) = 1.5 uM Binding affinity for matrix metalloproteinase-1 ChEMBL. 10229623
Ki (binding) = 1.5 uM Binding affinity for matrix metalloproteinase-1 ChEMBL. 10229623

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.